Skip to content

Cambridge Isotope Laboratories, Inc. Launches 12C Methane QG Diamond for Quantum Applications

Cambridge Isotope Laboratories, Inc. 2 mins read

TEWKSBURY, MA / ACCESSWIRE / May 27, 2024 / Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the release of highly enriched 12C methane with low nitrogen content called 12C Methane QG Diamond™ for quantum applications in the field of color and nitrogen vacancy CVD diamonds. 12C Methane QG Diamond will be useful for academics focused on quantum research, those developing diamonds with specific color properties or nitrogen-vacancy (NV) centers, and producers of industrial diamonds. The process of such applications begins with 12C-enriched methane.

"The creation of NV diamonds necessitates an exceptionally high concentration of 12C; minimal and controlled amounts of nitrogen," explains Joel Louette, who oversees business development for Emerging Markets at CIL. "Our interactions with clients from both academia and industry lead us to understand that the ideal material would possess a 12C enrichment of no less than 99.99% and contain nitrogen at levels below 1 part per million."

For over four decades, CIL has honed its skill in separating 13C isotopes through the process of cryogenic distillation. In doing so, CIL has consistently increased its 13C production capabilities to satisfy growing market needs, thereby reinforcing its position as a leader in this sector. Utilizing this deep-seated knowledge in cryogenic distillation, CIL has successfully developed a new 12C separation system, achieving the transition from design to operation in under three years.

Quantum magnetometers based on NV are revolutionizing inertial navigation, enhancing electric vehicle battery efficiency, healthcare, internet security, and may one day enable brain-to-machine interfaces.

About Cambridge Isotope Laboratories, Inc.

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit

Cambridge Isotope Laboratories, Inc.   

Phone: 1.978.749.8000   

Fax: 1.978.749.2768

Contact Information

Crissy Krisko

SOURCE: Cambridge Isotope Laboratories, Inc.


View the original press release on

More from this category

  • Science
  • 18/06/2024
  • 22:08
Takeda Pharmaceutical Company Limited

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Favorable Findings fromthe Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for Maintaining Stable Disease Course in CIDP…

  • Contains:
  • Medical Health Aged Care, Science
  • 18/06/2024
  • 12:30

WEHI spinout company set to revolutionise homegrown cancer treatments

Australia has cemented its role in becoming a major player in the next-generation of medicines with the launch of Ternarx – a globally competitive biotechnology company dedicated to finding new treatments for hard to treat cancers. The WEHI spinout is the first of its kind in Australia dedicated to developing targeted protein degrader medicines and technology, a powerful new tool for destroying disease-causing proteins that cannot be targeted by conventional drugs. Ternarx, which is backed by $15 million in funding from the Medical Research Future Fund’s (MRFF) Frontier Health and Medical Research initiative and by support from WEHI, has been…

  • Contains:
  • Science
  • 18/06/2024
  • 02:37
Nexeo Plastics

GPD Companies, Inc. Names Kurt Schuering as President and Chief Executive Officer

Paul Tayler to Retire and Remain on Board of DirectorsTHE WOODLANDS, TX / ACCESSWIRE / June 17, 2024 / GPD Companies, Inc. ("GPD"), an affiliate of One Rock Capital Partners, LLC ("One Rock"), today announced the appointment of Kurt Schuering as President and CEO, effective June 24, 2024. Paul Tayler will retire from his role as President and CEO and remain on GPD's Board of Directors. Schuering brings nearly 30 years of experience in the plastics industry and a proven track record of success, making him the ideal candidate to lead GPD into its next phase of growth and innovation.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.